Status In progress
Process STA
ID number 1117

Provisional Schedule

Expected publication 25 April 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Novartis
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin) (CAU not returned, not participating)
  Allergan (pemetrexed) (CAU not returned, not participating)
  Celgene (paclitaxel) (CAU not returned, not participating)
  Dr Reddy’s Laboratories (pemetrexed) (CAU not returned, not participating)
  Eli Lilly (pemetrexed) (CAU not returned, not participating)
  Hospira UK (cisplatin, carboplatin) (CAU not returned, not participating)
  Medac (paclitaxel) (CAU not returned, not participating)
  Pfizer (Crizotinib)
  Sun Pharma (carboplatin) (CAU not returned, not participating)
  Sandoz (cisplatin) (CAU not returned, not participating)
  Seacross pharmaceuticals (pemetrexed) (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
26 October 2017 Committee meeting: 1
30 May 2017 Invitation to participate
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance